Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases.

Filippou PS, Ren AH, Korbakis D, Dimitrakopoulos L, Soosaipillai A, Barak V, Frenkel S, Pe'er J, Lotem M, Merims S, Molina R, Blasutig I, Bogdanos DP, Diamandis EP.

Clin Chem Lab Med. 2018 May 16. pii: /j/cclm.ahead-of-print/cclm-2018-0139/cclm-2018-0139.xml. doi: 10.1515/cclm-2018-0139. [Epub ahead of print]

PMID:
29768245
2.

Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo.

Eisenberg G, Engelstein R, Geiger-Maor A, Hajaj E, Merims S, Frankenburg S, Uzana R, Rutenberg A, Machlenkin A, Frei G, Peretz T, Lotem M.

Cancer Immunol Res. 2018 Feb;6(2):127-138. doi: 10.1158/2326-6066.CIR-17-0383. Epub 2018 Jan 5.

PMID:
29305520
3.

A Rapidly Expanding Ulcer in the Armpit of a 48-year-old Man: A Quiz.

Renert-Yuval Y, Merims S, Maly A, Ramot Y.

Acta Derm Venereol. 2018 Mar 13;98(3):384-385. doi: 10.2340/00015555-2858. No abstract available.

4.

Adoptive cell therapy: past, present and future.

Cohen JE, Merims S, Frank S, Engelstein R, Peretz T, Lotem M.

Immunotherapy. 2017 Jan;9(2):183-196. doi: 10.2217/imt-2016-0112. Review.

PMID:
28128715
5.

Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.

Engelstein R, Merims S, Eisenberg G, Cohen J, Frank S, Hamburger T, Frankenburg S, Ron I, Isacson R, Grenader T, Steinberg H, Cohen CJ, Peretz T, Lotem M.

J Immunother. 2016 Oct;39(8):321-8. doi: 10.1097/CJI.0000000000000138.

PMID:
27564312
6.

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.

Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, Cohen J, Straussman R, Eisenberg G, Frankenburg S, Carmon E, Alaiyan B, Shneibaum S, Ozge Ayyildiz Z, Isbilen M, Mert Senses K, Ron I, Steinberg H, Smith Y, Shiloni E, Gure AO, Peretz T.

J Immunol Res. 2016;2016:8121985. doi: 10.1155/2016/8121985. Epub 2016 May 18.

7.

Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic.

Ollech A, Stemmer SM, Merims S, Lotem M, Popovtzer A, Hendler D, Hodak E, Didkovsky E, Amitay-Laish I.

Int J Dermatol. 2016 Apr;55(4):473-8. doi: 10.1111/ijd.13153. Epub 2016 Jan 29.

PMID:
26825962
8.

Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β.

Barak V, Leibovici V, Peretz T, Kalichman I, Lotem M, Merims S.

Anticancer Res. 2015 Dec;35(12):6755-60.

PMID:
26637892
9.

Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Pato A, Eisenberg G, Machlenkin A, Margalit A, Cafri G, Frankenburg S, Merims S, Peretz T, Lotem M, Gross G.

Clin Exp Immunol. 2015 Nov;182(2):220-9. doi: 10.1111/cei.12688. Epub 2015 Aug 28.

10.

Human T cell crosstalk is induced by tumor membrane transfer.

Uzana R, Eisenberg G, Merims S, Frankenburg S, Pato A, Yefenof E, Engelstein R, Peretz T, Machlenkin A, Lotem M.

PLoS One. 2015 Feb 11;10(2):e0118244. doi: 10.1371/journal.pone.0118244. eCollection 2015.

11.

Informal caregiving to older cancer patients: preliminary research outcomes and implications.

Goldzweig G, Merims S, Ganon R, Peretz T, Altman A, Baider L.

Ann Oncol. 2013 Oct;24(10):2635-40. doi: 10.1093/annonc/mdt250. Epub 2013 Jul 25.

PMID:
23894037
12.

Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells.

Eisenberg G, Uzana R, Pato A, Frankenburg S, Merims S, Yefenof E, Ferrone S, Peretz T, Machlenkin A, Lotem M.

J Immunol. 2013 Jun 1;190(11):5856-65. doi: 10.4049/jimmunol.1202879. Epub 2013 Apr 26.

13.

[Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].

Lotem M, Merims S, Frank S, Ospovat I, Peretz T.

Harefuah. 2012 Oct;151(10):585-8, 604. Review. Hebrew.

PMID:
23316667
14.

Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clones.

Uzana R, Eisenberg G, Sagi Y, Frankenburg S, Merims S, Amariglio N, Yefenof E, Peretz T, Machlenkin A, Lotem M.

J Immunol. 2012 Jan 15;188(2):632-40. doi: 10.4049/jimmunol.1101429. Epub 2011 Dec 7.

15.

HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.

Lotem M, Kadouri L, Merims S, Ospovat I, Nissan A, Ron I, Frankenburg S, Machlenkin A, Israel S, Steinberg H, Hamburger T, Peretz T.

Tissue Antigens. 2011 Sep;78(3):203-7. doi: 10.1111/j.1399-0039.2011.01709.x. Epub 2011 Jun 7.

PMID:
21644933
16.

Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy.

Merims S, Li X, Joe B, Dokouhaki P, Han M, Childs RW, Wang ZY, Gupta V, Minden MD, Zhang L.

Leukemia. 2011 Sep;25(9):1415-22. doi: 10.1038/leu.2011.99. Epub 2011 May 13.

17.

Human Vδ1-T cells regulate immune responses by targeting autologous immature dendritic cells.

Merims S, Dokouhaki P, Joe B, Zhang L.

Hum Immunol. 2011 Jan;72(1):32-6. doi: 10.1016/j.humimm.2010.10.011. Epub 2010 Oct 28.

PMID:
21035515
18.
19.

MHC class I-independent recognition of NK-activating receptor KIR2DS4.

Katz G, Gazit R, Arnon TI, Gonen-Gross T, Tarcic G, Markel G, Gruda R, Achdout H, Drize O, Merims S, Mandelboim O.

J Immunol. 2004 Aug 1;173(3):1819-25.

20.

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma.

Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, Isacson R, Kaduri L, Merims S, Frankenburg S, Peretz T.

Br J Cancer. 2004 Feb 23;90(4):773-80.

Supplemental Content

Loading ...
Support Center